2009: 102/5 (Nov) pp. 799-1006

Journal:Thrombosis and Haemostasis
ISSN:0340-6245

Archive
Issue

31 articles
1.
Advances in Understanding “High on-Treatment Platelet Reactivity”

Catherine P. M. Hayward

Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada

Thrombosis and Haemostasis 2009 102 5: 799-800

http://dx.doi.org/10.1160/TH09-09-0617

[Summary] [Free download]
2.
Heparin and its derivatives – Present and future

Job Harenberg1, Benito Casu2

1Medical Faculty Mannheim, Ruprecht-Karls-University Heidelberg, Clinical Pharmacology, Mannheim, Germany; 2G. Ronzoni Institute for
Chemical and Biochemical Research, Carbohydrate Science, Milan, Italy

Thrombosis and Haemostasis 2009 102 5: 801-803

http://dx.doi.org/10.1160/TH09-10-0698

[Summary] [Free download]
3.
From heparin to EP217609: The long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile

Maurice Petitou1; Vanessa Nancy-Portebois1; Guy Dubreucq1; Vincent Motte1; Dick Meuleman1,*; Martin de Kort2; Constant A. A. van Boeckel2; Gerard M. T. Vogel2; Jeffry A. J. Wisse2

1Endotis Pharma, Parc Biocitech, Romainville, France; 2N.V. Organon, part of Schering-Plough Corporation, Oss, The Netherlands

Thrombosis and Haemostasis 2009 102 5: 804-810

http://dx.doi.org/10.1160/TH09-01-0063

[Summary] [Free download]
4.
Development of idraparinux and idrabiotaparinux for anticoagulant therapy

Job Harenberg

Clinical Pharmacology, Faculty of Medicine Mannheim, Ruprecht-Karls University Heidelberg, Mannheim, Germany

Thrombosis and Haemostasis 2009 102 5: 811-815

http://dx.doi.org/10.1160/TH09-08-0555

[Summary] [Free download]
5.
Binding between heparin and the integrin VLA-4

Martin Schlesinger; Dirk Simonis; Patrick Schmitz; Juliane Fritzsche; Gerd Bendas

Department of Pharmacy, Rheinische Friedrich Wilhelms University, Bonn, Germany

Thrombosis and Haemostasis 2009 102 5: 816-822

http://dx.doi.org/10.1160/TH09-01-0061

[Summary] [Free download]
6.
Heparin, heparan sulfate and heparanase in inflammatory reactions

Jin-ping Li1; Israel Vlodavsky2

1Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden; 2Cancer and Vascular Biology Research Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel

Thrombosis and Haemostasis 2009 102 5: 823-828

http://dx.doi.org/10.1160/TH09-02-0091

[Summary] [Free download]
7.
Effects of polysaccharides enriched in 2,4-disulfated fucose units on coagulation, thrombosis and bleeding
Practical and conceptual implications

Roberto J. C. Fonseca; Gustavo R. C. Santos; Paulo A. S. Mourão

Laboratório de Tecido Conjuntivo, Hospital Universitário Clementino Fraga Filho and Programa de Glicobiologia, Instituto de Bioquímica Médica, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

Thrombosis and Haemostasis 2009 102 5: 829-836

http://dx.doi.org/10.1160/TH08-11-0773

[Summary] [Free download]
8.
Effects of a semi-synthetic N-,O-sulfated glycosaminoglycan K5 polysaccharide derivative in a rat model of cerebral ischaemia/reperfusion injury

Massimo Collino1; Sara Castiglia1; Marco Manoni2; Liana Salsini2; Jacopo Chini2; Emanuela Masini3; Roberto Fantozzi1

1Department of Anatomy, Pharmacology and Forensic Medicine, University of Turin, Turin, Italy; 2INALCO RSM S.p.A, Research Center, Montale, Pistoia, Italy; 3Department of Preclinical and Clinical Pharmacology, University of Florence, Florence, Italy

Thrombosis and Haemostasis 2009 102 5: 837-845

http://dx.doi.org/10.1160/TH09-01-0012

[Summary] [Free download]
9.
Heparins: Process-related physico-chemical and compositional characteristics, fingerprints and impurities

Lino Liverani1; Giuseppe Mascellani2; Franco Spelta1

1R&D Laboratories, Opocrin SpA, Corlo di Formigine, Modena, Italy; 2Freelance, Expert of Group 6 of European Pharmacopoeia, Bologna, Italy

Thrombosis and Haemostasis 2009 102 5: 846-853

http://dx.doi.org/10.1160/TH09-01-0064

[Summary] [Free download]
10.
From crisis to opportunity: A perspective on the heparin crisis

Ram Sasisekharan1; Zachary Shriver2

1Massachusetts Institute of Technology, Harvard - MIT Division of Health Sciences and Technology, Cambridge, Massachusetts, USA; 2Massachusetts Institute of Technology, Department of Biological Engineering, Cambridge, Massachusetts, USA

Thrombosis and Haemostasis 2009 102 5: 854-858

http://dx.doi.org/10.1160/TH09-02-0083

[Summary] [Free download]
11.
Detection and neutralisation of heparin by a fluorescent ruthenium compound

Helga Szelke1; Job Harenberg2; Roland Krämer1

1Anorganisch-Chemsiches Institut, Universität Heidelberg, Heidelberg, Germany; 2Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Universität Heidelberg, Medizinische Fakultät Mannheim, Mannheim, Germany

Thrombosis and Haemostasis 2009 102 5: 859-864

http://dx.doi.org/10.1160/TH09-03-0168

[Summary] [Free download]
12.
Structural features of low-molecular-weight heparins affecting their affinity to antithrombin

Antonella Bisio1; Davide Vecchietti1; Laura Citterio1; Marco Guerrini1; Rahul Raman2; Sabrina Bertini1; Giorgio Eisele1; Annamaria Naggi1; Ram Sasisekharan2; Giangiacomo Torri1

1Institute for Chemical and Biochemical Research “G. Ronzoni”, Milan, Italy; 2Harvard-MIT Division of Health Sciences & Technology, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA

Thrombosis and Haemostasis 2009 102 5: 865-873

http://dx.doi.org/10.1160/TH09-02-0081

[Summary] [Free download]
13.
The potential for circular dichroism as an additional facile and sensitive method of monitoring low-molecular-weight heparins and heparinoids

Timothy R. Rudd1*; Mark A. Skidmore1*; Scott E.Guimond1; Joseph Holman1; Jeremy E. Turnbull1; Robert M. Lauder2; David G. Fernig1; Edwin A. Yates1

1School of Biological Sciences, University of Liverpool, Liverpool, UK; 2School of Health and Medicine, Division of Biomedical and Life Sciences, Lancaster University, Bailrigg, Lancaster, UK

Thrombosis and Haemostasis 2009 102 5: 874-878

http://dx.doi.org/10.1160/TH08-12-0797

[Summary] [Free download]
14.
Activated partial thromboplastin time monitoring in patients receiving unfractionated heparin for venous thromboembolism in relation to clinical outcomes

Moshe Vardi; Arie Laor; Haim Bitterman

Division of Internal Medicine, Carmel Medical Center, Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

Thrombosis and Haemostasis 2009 102 5: 879-886

http://dx.doi.org/10.1160/TH09-06-0404

[Summary] [Free download]
15.
Heparin-induced thrombocytopenia (HIT II) – A drug-associated autoimmune disease

Götz Nowak

University Hospital Jena, Research Unit "Pharmacological Haemostaseology", Jena, Germany

Thrombosis and Haemostasis 2009 102 5: 887-891

http://dx.doi.org/10.1160/TH09-03-0209

[Summary] [Free download]
16.
Direct inhibitors of coagulation proteins – the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?

Volker Laux; Elisabeth Perzborn; Stefan Heitmeier; Georges von Degenfeld; Elke Dittrich-Wengenroth; Anja Buchmüller; Christoph Gerdes; Frank Misselwitz

Acute Care Research, Global Drug Discovery Research, Bayer Schering Pharma, Wuppertal, Germany

Thrombosis and Haemostasis 2009 102 5: 892-899

http://dx.doi.org/10.1160/TH09-02-0134

[Summary] [Free download]
17.
M118 – A rationally engineered low-molecular-weight heparin designed specifically for the treatment of acute coronary syndromes

Takashi Kei Kishimoto1; Yi Wei Qi1; Alison Long1; Ishan Capila1; Ram Sasisekharan2; Luis Guerrero3; Ian Fier1; James Roach1; Ganesh Venkataraman1

1Momenta Pharmaceuticals, Inc, Cambridge, Massachusetts, USA; 2Massachusetts Institute of Technology, Cambridge, Massachusetts, USA; 3Advanced Research Models, Inc, Norton, Massachusetts, USA

Thrombosis and Haemostasis 2009 102 5: 900-906

http://dx.doi.org/10.1160/TH09-02-0105

[Summary] [Free download]
18.
The Tainted Heparin Story: An Update

Marco Guerrini1; Zachary Shriver2; Antonella Bisio1; Annamaria Naggi1; Benito Casu1; Ram Sasisekharan2; Giangiacomo Torri1

1Institute for Chemical and Biochemical Research “G. Ronzoni”, Milan, Italy; 2Harvard-MIT Division of Health Sciences & Technology, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA

Thrombosis and Haemostasis 2009 102 5: 907-911

http://dx.doi.org/10.1160/TH09-02-0079

[Summary] [Free download]
19.
Pro: “Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation”

Jeff S. Healey

McMaster University, Hamilton, Ontario, Canada

Thrombosis and Haemostasis 2009 102 5: 912-913

http://dx.doi.org/10.1160/TH09-06-0369

[Summary] [Free download]
20.
Contra: “Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation”

Stavros Apostolakis; Eduard Shantsila; Gregory Y. H. Lip; Deirdre A. Lane

Haemostasis Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK

Thrombosis and Haemostasis 2009 102 5: 914-915

http://dx.doi.org/10.1160/TH09-08-0563

[Summary] [Free download]
  1-20 21-31
Next page

Articles

You've 1006 Article(s) in your Basket.

Thrombosis News

TH 107.5

Clinical Focus on GPIIb/IIIa inhibitors: In the May issue of Thrombosis and Haemostasis Armstrong...

TH 107.4

The April 2012 issue of Thrombosis and Haemostasis TH 107.4 is a Theme Issue by A. Schober, T....

Thrombosis and Haemostasis official organ of Spanish Society for Thrombosis and Haemostasis

Thrombosis and Haemostasis, founded in 1957, has become the official organ of the Spanish Society...